Opigolix
| CAS No. | 912587-25-8 | Cat. No. | BCP36620 |
| Name | Opigolix | ||
| Synonyms | ASP1707; ASP-1707; ASP 1707; | ||
| Formula | C25H19F3N4O5S | M. Wt | 544.5 |
| Description | Opigolix, also known as ASP1707, is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis. It was also under investigation for the treatment of prostate cancer. It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018. | ||
| Pathways | GPCR/G Protein | ||
| Targets | GnRH Receptor | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.